Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In Reply

In Reply COMMENTARY E APPRECIATE continued morbidity requiring a no- mained on open-label v3 mono- Dr Calabrese’s table change in their pharmacologi- therapy for longer than 2 years with commentary cal regimen. The decision to accept continued efficacy. on our study patients in any mood state was also This double-blind, placebo- W of v3 fatty ac- made with a longer-term study in controlled clinical trial of v3 fatty ids as a new treatment of bipolar dis- mind. Dr Calabrese correctly points acids in patients with bipolar disor- order. He correctly points out both out that any distinct acute anti- der was important not only in dem- the exciting aspects of v3 fatty ac- manic or antidepressant effects of the onstrating the efficacy of these es- ids as a therapy for patients with bi- v3 fatty acids will require studies de- sential lipids in patients with bipolar polar disorder, as well as the meth- signed to specifically measure such illness, but also in several other ways. odological shortcomings of our short-term effects. In addition, Dr First, the decision to study v3 fatty preliminary trial. Calabrese’s concerns over the ex- acids as putative mood stabilizers Dr Calabrese’s constructive clusion of 4 subjects from http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

In Reply

Stoll, Andrew L.; Marangell, Lauren B.
JAMA Psychiatry , Volume 56 (5) – May 1, 1999
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/in-reply-mtrkqSHUTW

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/archpsyc.56.5.415
Publisher site
See Article on Publisher Site

Abstract

COMMENTARY E APPRECIATE continued morbidity requiring a no- mained on open-label v3 mono- Dr Calabrese’s table change in their pharmacologi- therapy for longer than 2 years with commentary cal regimen. The decision to accept continued efficacy. on our study patients in any mood state was also This double-blind, placebo- W of v3 fatty ac- made with a longer-term study in controlled clinical trial of v3 fatty ids as a new treatment of bipolar dis- mind. Dr Calabrese correctly points acids in patients with bipolar disor- order. He correctly points out both out that any distinct acute anti- der was important not only in dem- the exciting aspects of v3 fatty ac- manic or antidepressant effects of the onstrating the efficacy of these es- ids as a therapy for patients with bi- v3 fatty acids will require studies de- sential lipids in patients with bipolar polar disorder, as well as the meth- signed to specifically measure such illness, but also in several other ways. odological shortcomings of our short-term effects. In addition, Dr First, the decision to study v3 fatty preliminary trial. Calabrese’s concerns over the ex- acids as putative mood stabilizers Dr Calabrese’s constructive clusion of 4 subjects from

Journal

JAMA Psychiatry – American Medical Association

Published: May 1, 1999

There are no references for this article.